Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study

Eur J Cardiothorac Surg. 2010 Mar;37(3):557-65. doi: 10.1016/j.ejcts.2009.08.012. Epub 2009 Sep 18.

Abstract

Objective: This study aims to investigate the effect of intrapleural polymeric films containing cisplatin on the local recurrence of malignant pleural mesothelioma in a rat tumour model.

Methods: An orthotopic rat recurrence model of malignant pleural mesothelioma was used. Five animals per group were evaluated. Polymeric films (4.5 cm diameter) for the local delivery of anticancer drug were constructed: hyaluronate, chitosan and the combined dual-layer polymers were loaded with cisplatin at a concentration of 100 mgm(-2). Animals without any adjuvant therapy were used as control. Mesothelioma cells were injected subpleurally in the anaesthetised rats. Six days later, a pleural tumour of 5.5mm was resected and a left pneumonectomy and pleural abrasion were performed. Thereafter, the cisplatin-loaded and unloaded films or cisplatin solution were intrapleurally applied, according to randomisation. After 6 days, animals were euthanised and organs harvested for morphological and histological evaluations. The primary endpoint was the volume of tumour recurrence. The secondary endpoints were treatment-related toxicity; cisplatin serum concentration evaluated at different time points; and cisplatin concentration in the pleura measured at autopsy. Analysis of variance (ANOVA) was used for statistical analysis. Bonferroni correction was applied for comparison between all groups.

Results: Tumour volume was significantly reduced in the hyaluronate cisplatin and hyaluronate-chitosan cisplatin groups in comparison to control groups (p=0.001 and p<0.0001, respectively). Animals treated with hyaluronate-chitosan cisplatin had a tumour recurrence significantly lesser than animals treated with cisplatin solution (p=0.003) and hyaluronate cisplatin (p=0.032). No toxicity related to the different treatments was observed. On postoperative days 1 and 2, cisplatin was detected in the serum at a concentration six- and sevenfold significantly higher in the hyaluronate cisplatin and hyaluronate-chitosan cisplatin groups, in comparison to cisplatin solution, and was maintained over time. Cisplatin levels in the pleura were higher in the hyaluronate-chitosan cisplatin group than in all others.

Conclusions: Hyaluronate-chitosan cisplatin was significantly effective in reducing tumour recurrence compared with cisplatin solution. Hyaluronate and hyaluronate-chitosan loaded with cisplatin assured significantly higher and more prolonged plasmatic drug concentrations than cisplatin solution without increasing toxicity.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics
  • Chemotherapy, Adjuvant / methods
  • Chitosan
  • Cisplatin / administration & dosage*
  • Cisplatin / pharmacokinetics
  • Hyaluronic Acid
  • Male
  • Mesothelioma / metabolism
  • Mesothelioma / pathology
  • Mesothelioma / prevention & control*
  • Mesothelioma / surgery
  • Neoplasm Recurrence, Local / prevention & control
  • Pharmaceutical Vehicles / administration & dosage*
  • Pharmaceutical Vehicles / pharmacokinetics
  • Pleural Neoplasms / metabolism
  • Pleural Neoplasms / pathology
  • Pleural Neoplasms / prevention & control*
  • Pleural Neoplasms / surgery
  • Pneumonectomy / methods
  • Polymers
  • Rats
  • Rats, Inbred F344
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Pharmaceutical Vehicles
  • Polymers
  • Hyaluronic Acid
  • Chitosan
  • Cisplatin